POLB |

Poolbeg Pharma #POLB – 2021 Annual Report and 2022 AGM Notice

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model , announces that its Annual Report and Accounts for the period ended 31 December 2021, a notice of the Annual General Meeting (“AGM”) 2022 and voting proxy form have been posted to shareholders. […]

Poolbeg Pharma #POLB – Interview

Co-founder & #COO of One Three Biotech, Brad Pryde catches up with brr mediauk on the #AI Deal with #POLB Poolbeg Pharma to identify new #drugs & treatments for #RSV. https://www.youtube.com/watch?v=TnKrI6xCt4s&ab_channel=PoolbegPharma

Poolbeg Pharma #POLB – Article – Further Assets

Artificial Intelligence gives unique insight to #drug discovery by spotting links that humans miss. These links identify new #drugs likely to succeed in clinic. In a crowded industry, #AI gives #POLB the edge Learn more: https://poolbegpharma.com/pipeline/further-assets/…

Poolbeg Pharma #POLB – Upcoming London Webinar

CEO of Poolbeg Pharma, will be presenting at next weeks London South East webinar. They look forward to providing updates on recent Company news. Register to attend: https://us02web.zoom.us/webinar/register/1716431929653/WN_ZJVzMqdWTgWYBetrouIuFg

Poolbeg Pharma #POLB – sign licence agreement with AnaBio Technologies to develop oral vaccine platform

CEO Of Poolbeg Pharma caught up with @Proactive_UK to discuss their oral vaccine discovery platform & rapidly expanding pipeline #POLB 001 POLB 002 POLB 003 Oral Vaccine Discovery Platform AI Powered Drug Programme Vaccine Discovery Platform PredictViral

Poolbeg Pharma #POLB – Licenses RNA-based immunotherapy asset

Broadcast Event Detail

Poolbeg Pharma #POLB – Growing a Capital Light Company. CEO Jeremy Skillington talks to Alan Green

Poolbeg Pharma #POLB – CEO Jeremy Skillington talks to Alan Green, and explains the ‘capital light’ model used by the company to grow the business. Jeremy talks about the three licensing deals signed by the company over the past few months, including the option agreement to licence MelioVac, the tie up with AnaBio Technologies and today’s […]